Drugs / MVA-MAGEA3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04908111 | Oct 2021 → Sep 2024 | esophageal squamous cell carcinoma, non-small cell lung carcinoma | Cancer Research UK | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-MAGEA3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04908111 ↗ |
| Modality | Vaccine | “two new vaccines called ChAdOx1-MAGEA3-NYESO, MVA-MAGEA3 and MVA-NYESO” NCT04908111 ↗ |
| Route | Intramuscular | “Route = IM injection” NCT04908111 ↗ |